Current Challenges and Opportunities for Improved Cannabidiol Solubility.

Hossain, KR; Alghalayini, A; Valenzuela, SM

Current Challenges and Opportunities for Improved Cannabidiol Solubility.

Hossain, KR Alghalayini, A

Valenzuela, SM

Permalink

Publisher:: MDPI
Publication Type:: Journal Article
Citation:: Int J Mol Sci, 2023, 24, (19), pp. 14514
Issue Date:: 2023-09-25

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download full textAdobe PDF (591.76 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Hossain, KR
dc.contributor.author	Alghalayini, A https://orcid.org/0000-0002-2308-0256
dc.contributor.author	Valenzuela, SM
dc.date.accessioned	2024-01-15T04:10:28Z
dc.date.available	2023-09-22
dc.date.available	2024-01-15T04:10:28Z
dc.date.issued	2023-09-25
dc.identifier.citation	Int J Mol Sci, 2023, 24, (19), pp. 14514
dc.identifier.issn	1422-0067
dc.identifier.issn	1422-0067
dc.identifier.uri	http://hdl.handle.net/10453/174438
dc.description.abstract	Cannabidiol (CBD), derived from the cannabis plant, has gained significant attention due to its potential therapeutic benefits. However, one of the challenges associated with CBD administration is its low bioavailability, which refers to the fraction of an administered dose that reaches systemic circulation. This limitation necessitates the exploration of various approaches to enhance the bioavailability of CBD, thus helping to maximize its therapeutic potential. A variety of approaches are now emerging, including nanoemulsion-based systems, lipid-based formulations, prodrugs, nanocarriers, and alternative routes of administration, which hold promise for improving the bioavailability of CBD and pave the way for novel formulations that maximize the therapeutic potential of CBD in various medical conditions. This opinion piece presents the current understanding surrounding CBD bioavailability and considers strategies aimed at improving both its absorption and its bioavailability.
dc.format	Electronic
dc.language	eng
dc.publisher	MDPI
dc.relation.ispartof	Int J Mol Sci
dc.relation.isbasedon	10.3390/ijms241914514
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	0399 Other Chemical Sciences, 0604 Genetics, 0699 Other Biological Sciences
dc.subject.classification	Chemical Physics
dc.subject.classification	3101 Biochemistry and cell biology
dc.subject.classification	3107 Microbiology
dc.subject.classification	3404 Medicinal and biomolecular chemistry
dc.subject.mesh	Cannabidiol
dc.subject.mesh	Solubility
dc.subject.mesh	Administration, Oral
dc.subject.mesh	Cannabis
dc.subject.mesh	Drug Delivery Systems
dc.subject.mesh	Cannabis
dc.subject.mesh	Cannabidiol
dc.subject.mesh	Drug Delivery Systems
dc.subject.mesh	Administration, Oral
dc.subject.mesh	Solubility
dc.subject.mesh	Cannabidiol
dc.subject.mesh	Solubility
dc.subject.mesh	Administration, Oral
dc.subject.mesh	Cannabis
dc.subject.mesh	Drug Delivery Systems
dc.title	Current Challenges and Opportunities for Improved Cannabidiol Solubility.
dc.type	Journal Article
utslib.citation.volume	24
utslib.location.activity	Switzerland
utslib.for	0399 Other Chemical Sciences
utslib.for	0604 Genetics
utslib.for	0699 Other Biological Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Centre for Health Technologies (CHT)
utslib.copyright.status	open_access	*
dc.date.updated	2024-01-15T04:10:25Z
pubs.issue	19
pubs.publication-status	Published online
pubs.volume	24
utslib.citation.issue	19

Abstract:

Cannabidiol (CBD), derived from the cannabis plant, has gained significant attention due to its potential therapeutic benefits. However, one of the challenges associated with CBD administration is its low bioavailability, which refers to the fraction of an administered dose that reaches systemic circulation. This limitation necessitates the exploration of various approaches to enhance the bioavailability of CBD, thus helping to maximize its therapeutic potential. A variety of approaches are now emerging, including nanoemulsion-based systems, lipid-based formulations, prodrugs, nanocarriers, and alternative routes of administration, which hold promise for improving the bioavailability of CBD and pave the way for novel formulations that maximize the therapeutic potential of CBD in various medical conditions. This opinion piece presents the current understanding surrounding CBD bioavailability and considers strategies aimed at improving both its absorption and its bioavailability.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/174438